Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUINTESSENTIAL-2: BMS-986393 CAR-T versus standard therapy in lenalidomide-refractory relapsed/refractory multiple myeloma
MOH_2024-07-04_013508Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arlocabtagene autoleucel in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Sep 2024; status: recruiting.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2024-07-04_013508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-04_013508.